Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 4/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936747 | 1.00 | HTR4 (0.57) | HTR4MCHR1KDM4EMEN1MAPT | |
| SCHEMBL1560183 | 0.93 | HTR4 (0.63) | HTR4MCHR1KDM4EMEN1MAPT | |
| SCHEMBL13880922 | 0.91 | HTR4 (0.53) | HTR4MCHR1KDM4EMEN1MAPT | |
| SCHEMBL12825889 | 0.89 | HTR4 (0.55) | HTR4MCHR1DRD4CHRM4CHRM5 | |
| SCHEMBL12825887 | 0.87 | HTR4 (0.66) | HTR4MCHR1KDM4EMEN1MAPT | |
| SCHEMBL12426664 | 0.86 | DRD4 (0.70) | MCHR1DRD4ADRA2CHTR2BHTR3A | |
| SCHEMBL12426323 | 0.86 | DRD4 (0.70) | MCHR1DRD4ADRA2CHTR2BHTR3A | |
| SCHEMBL13175736 | 0.85 | HTR4 (0.54) | HTR4MCHR1CHRM4CHRM5ADRA2C | |
| SCHEMBL13846090 | 0.85 | HTR4 (0.54) | HTR4MCHR1CHRM4CHRM5ADRA2C | |
| SCHEMBL3544670 | 0.85 | HTR4 (0.54) | HTR4MCHR1CHRM4CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | HTR4 3043/4885MCHR1 1932/4885KDM4E 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.